Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2011 | Original Article

Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer

Authors: Wei Yu, Li Chen, Yu-Qing Yang, John R. Falck, Austin M. Guo, Ying Li, Jing Yang

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2011

Abstract

Purpose

Cytochrome P450 (CYP) ω-hydroxylase, mainly consisting of CYP4A and CYP4F, converts arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) that induces angiogenic responses in vivo and in vitro. The present study examined the role of CYP ω-hydroxylase in angiogenesis and metastasis of human non-small cell lung cancer (NSCLC).

Methods

The effect of WIT003, a stable 20-HETE analog, on invasion was evaluated using a modified Boyden chamber in three NSCLC cell lines. A549 cells were transfected with CYP4A11 expression vector or exposed to CYP ω-hydroxylase inhibitor (HET0016) or 20-HETE antagonist (WIT002), and then ω-hydroxylation activity toward arachidonic acid and the levels of matrix metalloproteinases (MMPs) and VEGF were detected. The in vivo effects of CYP ω-hydroxylase were tested in established tumor xenografts and an experimental metastasis model in athymic mice.

Results

Addition of WIT003 or overexpression of CYP4A11 with an associated increase in 20-HETE production significantly induced invasion and expression of VEGF and MMP-9. Treatment of A549 cells with HET0016 or WIT002 inhibited invasion with reduction in VEGF and MMP-9. The PI3 K or ERK inhibitors also attenuated expression of VEGF and MMP-9. Compared with control, CYP4A11 transfection significantly increased tumor weight, microvessel density (MVD), and lung metastasis by 2.5-fold, 2-fold, and 3-fold, respectively. In contrast, WIT002 or HET0016 decreased tumor volume, MVD, and spontaneous pulmonary metastasis occurrences.

Conclusion

CYP ω-hydroxylase promotes tumor angiogenesis and metastasis by upregulation of VEGF and MMP-9 via PI3 K and ERK1/2 signaling in human NSCLC cells.

Granville CA, Dennis PA (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32:169PubMedCrossRef

Miyata N, Roman RJ (2005) Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 41:175PubMedCrossRef

Sun CW, Falck JR, Harder DR, Roman RJ (1999) Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33:414PubMed

Stec DE, Gannon KP, Beaird JS, Drummond HA (2007) 20-Hydroxyeicosatetraenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem 19:121PubMedCrossRef

Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, Sato MKameo K (2001) HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 133:325PubMedCrossRef

Seki T, Wang MH, Miyata N, Laniado-Schwartzman M (2005) Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N’-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol Pharm Bull 28:1651PubMedCrossRef

Chen P, Guo M, Wygle D, Edwards PA, Falck JR, Roman RJScicli AG (2005) Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166:615PubMedCrossRef

Sandra LA, Kristopher GM, Daniela NS, Richard JR, Andrew SG (2003) CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 284:1528

Guo M, Roman RJ, Falck JR, Edwards PAScicli AG (2005) Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N’-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A. J Pharmacol Exp Ther 315:526PubMedCrossRef

10.

Alexanian A, Rufanova VA, Miller B, Flasch A, Roman RJSorokin A (2009) Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Res 29:3819PubMed

11.

Guo AM, Sheng J, Scicli GM, Arbab AS, Lehman NL, Edwards PA, Falck JR, Roman RJScicli AG (2008) Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. J Pharmacol Exp Ther 327:10PubMedCrossRef

12.

Guo AM, Arbab AS, Falck JR, Chen P, Edwards PA, Roman RJScicli AG (2007) Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther 321:18PubMedCrossRef

13.

Yamane M, Abe A (2000) Omega-hydroxylation activity toward leukotriene B(4) and polyunsaturated fatty acids in the human hepatoblastoma cell line, HepG2, and human lung adenocarcinoma cell line, A549. J Biochem 128:827PubMed

14.

Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba RYokomise H (2008) The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 44:1057PubMedCrossRef

15.

Rasheed SA, Efferth T, Asangani IA, Allgayer H (2010) First evidence that the anti-malarial drug Artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127:1475PubMedCrossRef

16.

Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, Reed CE (2010) Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg 139:984PubMedCrossRef

17.

Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, Frias C, Diaz-Lopez A, Rodriguez-Jimenez FJ, Balibrea JLBenito M (2007) Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 17:217PubMed

18.

Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J, Treska V (2009) Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res 29:2513PubMed

19.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011PubMedCrossRef

20.

Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681PubMedCrossRef

21.

Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031PubMed

22.

Ortega N, L’Faqihi FE, Plouet J (1998) Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix. Biol Cell 90:381PubMedCrossRef

23.

Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9PubMedCrossRef

24.

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249PubMedCrossRef

25.

Wang DS, Miller R, Shaw R, Shaw G (1996) The Pleckstrin homology domain of human βI∑II spectrin is targeted to the plasma membrane in vivo. Biochem Biophys Res Commun 225:420PubMedCrossRef

26.

Cai KX, Tse LY, Leung C, Tam PK, Xu R, Sham MH (2008) Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin Cancer Res 14:939PubMedCrossRef

27.

Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T, Saiki I (1999) Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer 79:1121PubMedCrossRef

28.

Lv X, Wan J, Yang J, Cheng H, Li Y, Ao Y, Peng R (2008) Cytochrome P450 omega- hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion. Eur J Pharmacol 596:118PubMedCrossRef

29.

Duffy MJ, Duggan C (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37:541PubMedCrossRef

30.

Rofstad EK, Mathiesen B, Kindem K, Galappathi K (2006) Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 66:6699PubMedCrossRef

31.

Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185PubMedCrossRef

32.

Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST (1998) Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55:29PubMedCrossRef

33.

Kaplan RN, Psaila B, Lyden D (2007) Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 13:72PubMedCrossRef

34.

Guo M, Roman RJ, Fenstermacher JD, Brown SL, Falck JR, Arbab AS, Edwards PA, Scicli AG (2006) 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N’-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. J Pharmacol Exp Ther 317:97PubMedCrossRef

35.

Hukkanen J, Lassila A, Päivärinta K, Valanne S, Sarpo S, Hakkola J, Pelkonen O, Raunio H (2000) Induction and regulation of xenobiotic-metabolizing cytochrome P450 s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 22:360PubMed

36.

Jiang BH, Liu LZ (2008) AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 8:19PubMedCrossRef

37.

Qiao M, Sheng S, Pardee AB (2008) Metastasis and AKT activation. Cell Cycle 7:2991PubMedCrossRef

38.

Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22:395PubMedCrossRef

39.

Dhanasekaran A, Bodiga S, Gruenloh S, Gao Y, Dunn L, Falck JR, Buonaccorsi JN, Medhora M, Jacobs ER (2009) 20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells. Am J Physiol Heart Circ Physiol 296:H777PubMedCrossRef

Title: Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer
Authors: Wei Yu
Li Chen
Yu-Qing Yang
John R. Falck
Austin M. Guo
Ying Li
Jing Yang
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1521-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2011

Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases

Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells

Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells

Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer